- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Despite Increased Health Data Breaches, Fines Remain Rare
In a string of meetings and press releases, the federal government's health watchdogs have delivered a stern message: They are cracking down on insurers, hospitals, and doctors offices that don't adequately protect the security and privacy of medical records.
In a string of meetings and press releases, the federal government's health watchdogs have delivered a stern message: They are cracking down on insurers, hospitals and doctors offices that don't adequately protect the security and privacy of medical records.
"We've now moved into an area of more assertive enforcement," Leon Rodriguez, then-director of the U.S. Department of Health and Human Services' Office for Civil Rights, warned at a privacy and security forum in December 2012.
But as breaches of patient records proliferate — just this month, insurer Anthem revealed a hack that exposed information for nearly 80 million people — federal overseers have seldom penalized the health care organizations responsible for safeguarding this data, a ProPublica review shows.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
